Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Paul van der Leest1, Birgitta Hiddinga2, Anneke Miedema1, Maria L. Aguirre Azpurua1, Naomi Rifaëoa1, Arja ter Elsta1, Wim Timens1, Harry J. M. Groen2, Léon C. van Kempen1, T. Jeroen N. Hiltermann2 and Ed Schuuring1

1 Department of Pathology, University of Groningen, University Medical Center Groningen, The Netherlands
2 Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, The Netherlands

Keywords
cfDNA; droplet digital PCR; ICI treatment response monitoring; NSCLC; PD-L1

Correspondence
E. Schuuring. Department of Pathology (HPC EA10), University Medical Center Groningen, Hanzeplein 1, PO Box 30001, 9700 RB, Groningen, The Netherlands
Tel: (+31) 50 361 9637; (+31) 50 361 4686/0020 (secr)
E-mail: e.schuuring@umcg.nl

Immunotherapy for metastasized non-small-cell lung cancer (NSCLC) can show long-lasting clinical responses. Selection of patients based on programmed death-ligand 1 (PD-L1) expression shows limited predictive value for durable clinical benefit (DCB). We investigated whether early treatment effects as measured by a change in circulating tumor DNA (ctDNA) level is a proxy of early tumor response to immunotherapy according to response evaluation criteria in solid tumors v1.1 criteria, progression-free survival (PFS), DCB, and overall survival (OS). To this aim, blood tubes were collected from advanced-stage lung adenocarcinoma patients (n = 100) receiving immune checkpoint inhibitors (ICI) at baseline (t0) and prior to first treatment evaluation (4–6 weeks; t1). Nontargetable (driver) mutations detected in the pretreatment tumor biopsy were used to quantify tumor-specific ctDNA levels using droplet digital PCR. We found that changes in ctDNA levels were strongly associated with tumor response. A >30% decrease in ctDNA at t1 correlated with a longer PFS and OS. In total, 80% of patients with a DCB of ≥26 weeks displayed a >30% decrease in ctDNA levels. For patients with a PD-L1 tumor proportion score of ≥1%, decreasing ctDNA levels were associated with a higher frequency of DCB (80%) and a prolonged median PFS (85 weeks) and OS (101 weeks) compared with patients with no decrease in ctDNA (34%; 11 and 39 weeks, respectively). This study shows that monitoring of ctDNA dynamics is an easy-to-use and promising tool for assessing PFS, DCB, and OS for ICI-treated NSCLC patients.

Abbreviations
cfDNA, circulating cell-free DNA; CD8+, cluster of differentiation 8 positive; CI, confidence interval; CR, complete response; CT, computed tomography; ctDNA, circulating tumor DNA; DCB, durable clinical benefit; ddPCR, droplet digital PCR; ECOG PS, Eastern Cooperative Oncology group performance-status score; EGFR, epidermal growth factor receptor; FFPE, formalin-fixed paraffin-embedded; HR, hazard ratio; ICI, immune checkpoint inhibitors; KRAS, kirsten rat sarcoma viral oncogene homolog; MET, mesenchymal epithelial transition factor; NSCLC, non-small-cell lung cancer; OS, overall survival; PD, progressive disease; PD-L1, programmed death-ligand 1; PET/CT, positron emission tomography/computed tomography; PFS, progression-free survival; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PR, partial response; RECIST v1.1, response evaluation criteria in solid tumors version 1.1; SD, stable disease; STK11, serine/threonine kinase 11; TP53, tumor protein p53; TPS, tumor proportion score.
1. Introduction

Treatment with immune checkpoint inhibitors (ICI) for advanced non-small-cell lung cancer (NSCLC) patients without targetable genetic alterations demonstrated long-lasting therapy response and OS in selected patients [1–5]. Programmed death-ligand 1 (PD-L1) protein expression in the pretreatment tumor tissue determines eligibility for immunotherapy targeting PD-1 or PD-L1 inhibitors with or without chemotherapy. First-line treatment with pembrolizumab is currently standard of care for patients with advanced NSCLC. However, even in patients with tumors having a high PD-L1 expression (≥ 50% of tumor cells), a DCB of treatment is achieved in less than half of the cases [3,6,7]. Nivolumab monotherapy as treatment beyond first line resulted in 4-year OS of 14% (95% confidence interval [CI]: 11–17%) for all patients (n = 664), 19% (95% CI: 15–24%) for those with at least 1% PD-L1 expression, and 11% (95% CI: 7–16%) for those with less than 1% PD-L1 expression [4]. Although eligibility criteria for immunotherapy are defined, there is an urgent demand for improved predictive and prognostic biomarkers that define which patients benefit from treatment. The ability to identify nonresponders at an early stage of ICI treatment could avoid severe toxicities associated unnecessary continuation of ICI treatment and reduce the financial burden on the healthcare system.

Solely relying on tumor PD-L1 expression has proven clear limitations to accurately predict tumor response by response evaluation criteria in solid tumors (RECIST) v1.1 criteria [8]. Furthermore, early on-treatment radiologic assessment of tumor response cannot always predict durability of response because patients with initial pseudoprogression or stable disease (SD) may have durable responses comparable to patients who do have a radiological tumor response [4]. Therefore, a biomarker that better predicts or can monitor treatment effects for individual patients, alone or in combination with PD-L1, is increasingly demanded [9]. Recent studies showed that monitoring the circulating tumor-derived DNA (ctDNA) fraction in the circulating cell-free DNA (ccfDNA) in plasma samples, as a surrogate for biologic tumor response, correlates with individual early tumor responses and clinical outcome to treatment in several cancer types [10,11], including NSCLC patients treated with ICI using expensive and complex next-generation sequencing (NGS) methodologies on serial plasma ccfDNA [12–16].

Droplet digital PCR (ddPCR) analysis of plasma ctDNA is routinely used for clinical applications to detect targetable mutations in epidermal growth factor receptor (EGFR) [17–19], KIT [20], and BRAF [21,22], with an analytical sensitivity of 0.1–0.01% and specificity > 99% [19,20,22,23]. Here, we focused on a sensitive ddPCR test to monitor changes in ctDNA in plasma from advanced lung adenocarcinoma patients receiving single-agent ICI. For this study, the target ctDNA was selected from the Pathology archives that reported on clinically relevant mutations determined by NGS analysis of the primary tumor in routine clinical practice. Patients with tumors harboring a nontargetable somatic mutation such as pathogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), and who were therefore treated with single-agent ICI, were prospectively included. In addition to patients with KRAS mutations, patients with non-KRAS-mutated tumors (e.g., BRAF and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [PIK3CA] mutations) were included to rule out KRAS mutation-specific observations. To date, only three other studies with relatively small cohorts of advanced NSCLC patients treated with ICI selected tumor-informed nontargetable somatic mutations for monitoring ctDNA levels using a single-gene assay [24–26]. Here, we investigated changes in ctDNA levels as a proxy of early tumor response to ICI for progression-free survival (PFS), DCB, and OS in cohort of 100 patients with advanced lung adenocarcinoma using this approach.

2. Materials and methods

2.1. Patient selection

Patients were recruited between October 2015 and November 2019. In total, 100 patients with advanced adenocarcinoma receiving ICI treatment were eligible for this study. Mutation analysis via NGS of the pretreatment formalin-fixed paraffin-embedded (FFPE) tissue biopsies was performed in the routine diagnostic setting. These results were available for this study. Follow-up data for all patients were obtained up to the database lock (October 9, 2020). Eligibility criteria were ≥ 18 years of age, Eastern Cooperative Oncology Group performance-status score (ECOG PS) ≤ 1, advanced-stage adenocarcinoma and measurable disease assessed by means of computed tomography (CT) according to RECIST v1.1 [27]. This study is a larger cohort based on CA209-759 study (NTR 6158) and was approved by the Medical Ethical Committee (METc, 2010/109) of the University Medical Center Groningen (UMCG). The study methodologies were
conformed to the standards set by the Declaration of Helsinki. All patients provided written informed consent.

2.2. Radiological evaluation

Positron emission tomography/CT imaging was assessed at baseline in all patients. Tumor evaluation with CT was performed every 6 weeks in the first year of ICI therapy, thereafter every 12 weeks until disease progression. RECIST v1.1 criteria were used to assess tumor response. CtDNA dynamics were used to predict radiological response and DCB. Progressive disease (PD) is defined as an increase in tumor volume of > 20% or appearance of new lesions. Partial response (PR) is defined as a decrease in tumor volume of > 30%; complete response (CR) as response showing that all lesions (both target and nontarget) are less than 10mm in the long axis (except lymph nodes which have to be smaller than 10mm in short axis). SD is attributed if neither the criteria for PD, PR or CR are met.

2.3. Plasma collection and ccfDNA extraction

Blood samples were available in either vacutainer EDTA tubes (vacutainer #367525, Becton Dickinson, Franklin Lakes, NJ, USA; until December 2017) or cell-free DNA blood Streck collection tubes (BCTs; Streck, Omaha, NE, USA), since January 2018. Processing of cell-free plasma and ccfDNA extraction was according to standard operating procedure as reported previously [28,29]. In short, EDTA blood samples were processed within 4 h and Streck samples within 24 h. Subsequent processing consisted of a slow (for EDTA: 820 g, 10 min, 4 °C; for Streck: 1600 g, 10 min, 20 °C) and subsequent fast (16 000 g, 10 min, 4 °C) centrifugation step. Plasma was stored as 1 mL aliquots at −80 °C until ccfDNA extraction. CcfDNA was extracted from ~ 2 mL plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations and as reported previously [28]. CcfDNA was eluted in 52 μL of AVE buffer and its concentration was measured by Qubit™ dsDNA HS assay kit on a Qubit™ 2.0 fluorometer (Thermo Fisher Scientific, Waltham, MA, USA).

To determine the most appropriate timepoint after start ICI therapy to measure changes in ctDNA levels, a subset of 27 patients was first selected from whom plasma was stored of several timepoints between baseline and disease progression, as well as four patients who displayed rapid disease progression (within 6 weeks; Table S1). For this subset, 164 plasma samples were collected with on average 6 (2–12) samples per patient. After the appropriate timepoint of follow-up was established, all 100 patients were analyzed at baseline (t0) and at 4- to 6-week follow-up (t1).

2.4. Tumor specimen handling and tissue NGS

As routine workup of suspected lung cancer, tumor tissue was obtained by a bronchoscopy, transthoracic biopsy or an endoscopic ultrasound procedure (endobronchial ultrasound/endoscopic ultrasound). Tissue samples were processed and diagnosed following routine pathology procedures. Following Dutch guidelines, FFPE-pretreatment tissue samples of all adenocarcinomas from patients with metastasized NSCLC were subjected to sequence analysis by targeted NGS for mutations in relevant predictive markers including EGFR, BRAF, KRAS, PIK3CA, erb-b2 receptor tyrosine kinase 2 and MET [30] in the NEN-EN-ISO15189-accredited laboratory for molecular pathology at the UMCG as reported previously [20,31]. Molecular results are reported in the Dutch nationwide pathology registry (PALGA). For this study, lung adenocarcinoma patients were selected with a somatic mutation for which no targetable drugs were available and therefore were treated with ICI (see Table 1 for overview of mutations). Out of 22 patients with non-KRAS mutations, 11 patients with a targetable mutation (e.g., BRAF V600E, EGFR L858R, or EGFR T790M) were included following progression on tyrosine kinase inhibitors (TKIs) or as a last resort treatment. PD-L1 expression was detected with the Ventana PD-L1 (SP263) Assay (RTU, conformité Européene-in vitro diagnostic) on a Ventana Benchmark Ultra immunostain on pretreatment tissue biopsies. Staining was scored by an experienced pulmonary pathologist (WT) according to international classification criteria and reported as tumor proportion score (TPS) for 87 patients [32].

2.5. Quantitative ctDNA analysis

For each patient, a tumor-specific ddPCR assay using nontargetable (driver) mutations present in the pretreatment biopsy was selected in order to detect and quantify the tumor-specific mutations in ccfDNA (Table S2). DdPCR analysis was performed as reported previously [20,23,28]. In short, ccfDNA (median 5.4 ng, 1.3–61 ng) was emulsified into 10,000–20,000 droplets by the QX200™ droplet generator (Bio-Rad Laboratories, Pleasanton, CA, USA) and
Monitoring ctDNA for treatment response prediction

Table 1. Clinical and pathological characteristics. N/A, not available.

| Characteristic                        | N  |
|---------------------------------------|----|
| Patients                              | 100|
| Median age                            | 66 (29–85) |
| Sex                                   |    |
| Male                                  | 53 (53%) |
| Female                                | 47 (47%) |
| ECOG PS                               |    |
| 0                                     | 42 (42%) |
| 1                                     | 49 (49%) |
| 2                                     | 7 (7%)  |
| 3                                     | 2 (2%)  |
| Smoking status                        |    |
| Current                               | 39 (39%) |
| Former                                | 58 (58%) |
| Never                                 | 3 (3%)  |
| Immunotherapy                         |    |
| Atezolizumab                          | 2 (2%)  |
| Durvalumab                            | 1 (1%)  |
| Nivolumab                             | 69 (69%) |
| Pembrolizumab                         | 28 (28%) |
| Previous lines of (chemo)therapies    |    |
| 0                                     | 25 (25%) |
| 1                                     | 57 (57%) |
| 2                                     | 12 (12%) |
| 3                                     | 6 (6%)  |
| KRAS mutations                        |    |
| c.350–G>C p.(G12A)                    | 4 (4%)  |
| c.347–T>C p.(G12C)                    | 37 (37%) |
| c.349–A>G p.(G12D)                    | 9 (9%)  |
| c.349–C>T p.(G12R)                    | 1 (1%)  |
| c.350–T>G p.(G12V)                    | 18 (18%)|
| c.370–G>T p.(G13C)                    | 1 (1%)  |
| c.380–A>G p.(G13D)                    | 3 (3%)  |
| c.182A>C p.(Q61H)                     | 3 (3%)  |
| c.181C>A p.(Q61K)                     | 1 (1%)  |
| c.182A>T p.(Q61L)                     | 1 (1%)  |
| Non-KRAS mutations                    |    |
| BRAF c.1397G>C p.(G466A)              | 1 (3%)  |
| BRAF c.1397G>T p.(G466V)              | 2 (1%)  |
| BRAF c.1406G>C p.(G469A)              | 3 (1%)  |
| BRAF c.1406G>T p.(G469V)              | 1 (1%)  |
| BRAF c.1799_1801del p.(V600_K601delinsE) | 1 (1%) |
| BRAF c.1799T>A p.(I600E)              | 5 (5%)  |
| EGFR c.2310_2311ins(GGC p.(D770_N771insG)) | 1 (1%) |
| EGFR c.2155G>A p.(G719S)              | 1 (1%)  |
| EGFR c.2316_2321dup p.(H773_V774dup)  | 1 (1%)  |
| EGFR c.2573T>G p.(L858R)              | 1 (1%)  |
| PIK3CA c.1624G>A p.(E542K)            | 3 (5%)  |
| PIK3CA c.1633G>A p.(E545K)            | 2 (3%)  |
| PD-L1 TPS                             |    |
| < 1%                                  | 34 (34%) |
| ≥ 1–49%                               | 17 (17%) |
| ≥ 50%                                 | 35 (35%) |
| N/A                                   | 14 (14%) |

amplified with ddPCR™ supermix (Bio-Rad) and the primers and probes (Table S2) into a final volume of 20 µL. Mutant (FAM-labeled) or wild-type (HEX-labeled) fluorescent quantitative signals were detected by the QX200™ platform (Bio-Rad). DdPCR results were analyzed with QuantaSoft™ analytical software (Bio-Rad). Droplet counts were used to calculate the number of mutant copies per mL of plasma. The variant allelic frequency was determined by QuantaSoft™ Analysis Pro. Samples were regarded as positive if ≥3 mutant droplets were detected and negative if <3 mutant droplets with at least 330 total positive (wild-type and mutant) droplets were detected (ensuring an analytical sensitivity <1%). Because previous assessments of the precision of the ddPCR tests that are used in this study revealed a 30% technical variance [23], we set the minimum threshold at 30% and we only consider changes in mutant ctDNA levels greater than 30% as a true increase or decrease. In addition, we evaluated more stringent thresholds of 40% and 50% that were previously reported to be informative [12,33,34]. To confirm the changes in ctDNA levels detected with ddPCR, a fully automated real-time PCR Idylla™ ctKRAS Mutation Assay (Biocartis, Mechelen, Belgium) was performed as reported previously [35,36]. All analyses included mutation-positive, wild-type, and no template controls. All standard precautions were taken to avoid contamination of amplification products using separate laboratories for pre- and post-PCR handling. Clinical and laboratory test outcomes were independently added into the database.

2.6. Statistical analysis

Descriptive statistics were used for patient and tumor characteristics. PFS and OS were defined as the period between the date of start of ICI to the date of PD or date of death, respectively. Data were censored at the date of last follow-up in absence of an event. Kaplan–Meier survival data were stratified for mutant ctDNA data and compared with the log-rank test. To compare ctDNA dynamics with PD-L1 TPS, Kaplan–Meier curves were stratified according to the PD-L1 TPS. Radiological reports and liquid biopsy test results were assessed independently. Correlation between the KRAS G12/13 screening ddPCR assay and Idylla™ ctKRAS Mutation Assay results was determined using Pearson’s correlation coefficient and agreement was performed using Cohen’s κ. Differences in the rate of DCB were assessed with a Mann–Whitney U test. GRAPHPAD PRISM 8.4.2 (GraphPad Software, San Diego, CA, USA) or spss version 25 software (IBM SPSS Statistics, Armonk, NY, USA) were used for all statistical analysis, wherein a P-value < 0.05 was considered significant.
3. Results

3.1. Patient characteristics

Next-generation sequencing analysis of the pretreatment FFPE tissue biopsies identified 78 tumor samples with mutations in KRAS (78%) and 22 with a non-KRAS mutation (22%). All clinical and pathological characteristics are summarized in Table 1. Most patients (n = 69) were treated with nivolumab 3 mg kg\(^{-1}\) body weight intravenously every 2 weeks or pembrolizumab 200 mg (n = 28 patients) every 3 weeks intravenously (Table 1). In addition, two patients were treated with atezolizumab 1200 mg every 2 weeks and one patient with durvalumab 20 mg kg\(^{-1}\) every 2 weeks. The median number of weeks from start ICI until tumor response was 6 weeks (2–55 weeks). Follow-up CT imaging was not performed in eight patients (8%) as clinical PD already occurred prior to the first radiological evaluation. Sixty-six patients (66%) had an early tumor response, defined by a tumor response according to RECIST v1.1 within 6 weeks after start ICI treatment. A late tumor response, defined by tumor response according to RECIST v1.1 after 12 weeks, was observed in 18 (18%). A DCB is defined by a clinical response with at least SD lasting ≥ 6 months as reported previously [8], which was achieved in 39 patients (39%).

3.2. Optimal timepoint to measure changes in ctDNA levels associated with durable tumor response

Twenty-seven patients with a KRAS or BRAF (non-V600E) mutation in the primary tumor from whom plasma was available at several timepoints during ICI treatment, predominantly at 1, 2, 4, and 6 weeks after initiation, were selected (Table S1) to determine the optimal timepoint to measure changes in ctDNA levels associated with therapy response effects. CcfDNA was analyzed to quantify mutant ctDNA copies. Tumor response patterns could be divided into five typical patterns for CR, PR, SD, PD, and ctDNA-negative patients (see examples in Fig. S1A–E). The ctDNA patterns of all responding patients (n = 11) revealed an initial spike in ctDNA levels prior to a decrease in ctDNA levels (Fig. S2A). One exceptional case is discussed separately (Fig. S3). In samples at 4–6 weeks, most of the responders (70–89%) showed a > 30% decrease, while in most of the nonresponders (55–75%) ctDNA levels at 4–6 weeks increased (Fig. S2B). Spider plot analysis supported the predictive value of ctDNA analysis 4–6 weeks after start therapy (t1). Patients with increased, stable or nondetectable (considered as negative) levels of ctDNA demonstrated early disease progression, of whom 14/16 (88%) have deceased. The majority of patients with decreasing ctDNA demonstrated a response, of whom 10/11 (91%) were alive after at least 80 weeks (Fig. 1).

Fig. 1. Spider plot analysis of radiological response according to the RECIST v1.1 criteria and changes in mutant ctDNA levels. CtDNA levels were determined by the difference in mutant copies per mL of plasma at baseline (t0) and 4–6 weeks after start of ICI treatment (t1). Dashed lines indicate a 20% increase and 30% decrease in tumor volume compared with baseline. The cross symbol indicates the patient’s death at that point in time. One exceptional case is described in Fig. S3. CtDNA increasing, 30% more mutant copies at t1 compared with t0; ctDNA decreasing, 30% less mutant copies at t1 compared with t0; ctDNA-negative, driver mutation in tissue not detected in plasma; ctDNA stable, observed change in mutant copies at t1 compared with t0 was ≤ 30%.
3.3. Validation of KRAS ddPCR analysis with Idylla ctKRAS

To confirm the levels of KRAS-mutated ctDNA detected in cell-free plasma using ddPCR analysis, 89 samples with sufficient plasma were also analyzed with the Idylla™ ctKRAS Mutation Assay as an independent plasma-based test. Based on the number of mutant copies per mL plasma, ddPCR and Idylla revealed similar results ($r^2 = 0.94$, black line; $r^2 = 0.64$ omitting six cases with very high levels, blue line; Fig. S4). When comparing changes in KRAS mutant ctDNA levels between t0 and t1, 13 of the 15 patients showed a similar association with clinical response represented by an almost perfect agreement when comparing ddPCR with Idylla ($k = 0.84$). These data confirmed that quantitative ctDNA analysis using ddPCR reliably predicted changes in mutant ctDNA levels.

3.4. Changes in ctDNA levels as an early marker of durable clinical benefit

To validate the potential value of monitoring ctDNA levels, ddPCR analysis was performed on cfctDNA from 100 lung adenocarcinoma patients treated with mono-immunotherapy. When ctDNA was detected at t0, a significant difference in the number of mutant copies per mL of plasma was observed between patients with no clinical response and patients who had a DCB (Fig. S5A). Patients with high mutant ctDNA levels at t0 showed a poorer PFS ($P < 0.001$) and OS ($P < 0.0001$) compared with low mutant copy levels (Fig. S5B,C). No ctDNA was detected at t0 in 31 patients (31%). CtDNA-negative patients were represented both in 21 of the 63 nonresponders (33%) and 10 of 37 of durable responders (27%) (Fig. S5A, red dots).

Patients with a decrease in ctDNA levels at t1 had the best median PFS and OS (Fig. 2A,B). Patients with both stable ctDNA (change at t1 compared with t0 ≤ 30%) or increased (> 30%) ctDNA levels showed similar poor responses. Therefore, patients with a ctDNA increase or ctDNA stable levels were grouped as no ctDNA decrease in subsequent analyses. Although 70% of patients without detectable ctDNA (16/23) showed early disease progression (within 6 months), they did perform better than patients with increasing or stable levels of ctDNA, but worse than those with a decrease in ctDNA was observed at t1 (Fig. 2B). Therefore, patients without detectable ctDNA were regarded as a separate group.

Analysis excluding ctDNA-negative patients revealed that patients with decreasing mutant ctDNA levels had a significantly improved PFS (hazard ratio [HR]: 0.41 [0.19–0.52]; $P < 0.0001$) compared with patients who did not (no decrease in mutant ctDNA), resulting in a longer median PFS (43 vs 6 weeks; Fig. 2C) and OS (125 vs 29 weeks; HR: 0.32 [0.16–0.46]; $P < 0.0001$; Fig. 2D). Using a higher threshold of 50% for ctDNA response (Fig. S6) revealed comparable results as observed for 30% with only a slightly improved HRs for PFS and OS.

To exclude that the observed association between ctDNA levels and treatment response was due to the specific activity of KRAS mutations, the PFS and OS comparing presence ($n = 78$) or absence ($n = 22$) of KRAS mutations in the pretreatment tumor tissue were evaluated. This analysis revealed no significant difference in PFS and OS (Fig. S7).

3.5. PD-L1 expression in pretreatment tissue biopsies and ctDNA dynamics

Progressive disease-L1 expression data were available for 87 patients. Thirty-five patients (40%) were PD-L1 negative (TPS < 1%) and 52 (60%) had a PD-L1 TPS ≥ 1% (of whom 35 with TPS ≥ 50%; Table 1). In this cohort, patients with a PD-L1 TPS of ≥ 1% had a longer PFS (25 vs 6 weeks; HR: 0.46 [0.22–0.61]; $P < 0.001$) and OS (83 vs 32 weeks; HR: 0.57 [0.32–0.92]; $P < 0.05$) than PD-L1 negative patients (Fig. S8).

In patients with a PD-L1 TPS of ≥ 1%, decreased ctDNA levels further improved both PFS (85 vs 11 weeks; HR: 0.42 [0.22–0.78]; $P < 0.01$) and OS (101 vs 39 weeks; HR: 0.37 [0.19–0.72]; $P < 0.01$; Fig. 3A, B; Fig. S9A,B). Interestingly, in a subset of PD-L1-negative patients (TPS of < 1%), decreased ctDNA levels were also associated with prolonged PFS and OS (Fig. 3C,D; Fig. S9C,D). The effect of a ctDNA decrease on PFS was stronger for patients with PD-L1 expressing tumors compared with patients with PD-L1-negative tumors (HR: 0.40 [0.14–0.80], $P < 0.05$; data not shown).

4. Discussion

When a tumor-derived molecular aberration is detected in plasma, this can potentially be used to monitor early tumor response to ICI. In the current study, we demonstrate the value of measuring ctDNA levels using ddPCR at baseline (t0) and follow-up (4–6 weeks, t1) as a minimally invasive monitoring tool for response to ICI monotherapy. The group of patients who displayed a decrease in
mutant copies had a longer PFS, OS, and DCB compared with those without decrease in ctDNA levels. Furthermore, patients who displayed a reduction in mutant tumor DNA in circulation and had a PD-L1 expressing tumor demonstrated an even better PFS, OS, and DCB. The data indicate that the combination of PD-L1 expression and reduction in ctDNA is a stronger monitoring tool for response to ICI than PD-L1 expression or change in ctDNA alone.

Detection of tumor-derived DNA in liquid biopsy has enabled assessment of mutation profiles in plasma of cancer patients at different stages of disease in a minimally invasive manner [37]. Recent studies advocate NGS of pretreatment plasma samples as the most appropriate approach to identify mutants for disease monitoring of virtually all patients. Subsequently, a selection of these mutations can be monitored in plasma over time. In current clinical practice however, high cost of plasma-derived ccfDNA NGS for all patients is cost-prohibitive. In contrast, it is currently common practice to perform molecular profiling on a tumor tissue biopsy with broader NGS mutation panels. Mutation profiling of tumor biopsies not only resulted in the identification of clinical-relevant drug-gable targets, but also in tumor-specific variants that may be detected in circulation. In the current study, the tumor-informed ddPCR analysis of ctDNA has demonstrated promise as a cost-effective monitoring tool.

We studied dynamics of mutant ctDNA levels prior to radiological evaluation in plasma using mutations that were detected in the pretreatment tissue biopsies as part of routine molecular diagnostics. In the first 2 weeks of treatment, a spike in ctDNA levels was observed in 61% of all patients with measurable ctDNA at baseline (14/23), and in 70% of patients who eventually demonstrated treatment response (Fig. S2). This transient spike in ctDNA was reported previously for KRAS and EGFR in NSCLC, probably reflecting tumor DNA release by death of tumor cells upon initiation of systemic treatment [11,12,38]. The
strong increase in ctDNA within 2 weeks after start of therapy that was observed in 15 patients was not predictive for DCB (data not shown). Our analysis demonstrated that at least a 30% decrease in ctDNA levels at 4–6 weeks after initiation of treatment (t1) correlated with a longer PFS and OS in response to ICI treatment, as well as an increased rate of DCB (Table S3). A decrease in mutant ctDNA levels was associated with a superior median PFS (43 weeks, HR: 0.42 [0.22–0.78]) and OS (11 weeks, HR: 0.37 [0.19–0.52]) compared with increasing or stable (red) ctDNA levels (PFS 6 weeks; OS 29 weeks). These results are comparable to three other studies with small cohorts of advanced NSCLC patient (respectively 14 [24], 34 [25], and 15 cases [26]) with nontargetable mutations detected in tumor biopsy treated with ICI. Despite that KRAS-mutated tumors were associated with high PD-L1 expression and consequently with increased tumor responses toward PD-L1 inhibition [2,39–41], no discrepancies between tumor harboring KRAS or other mutations were observed in our cohort.

In the current study, the median PFS of patients with a PD-L1 TPS ≥1% is just 25 weeks. Further dividing PD-L1 TPS in 1-49% and ≥50%, which is generally applied in current literature, did not reveal significant differences regarding PFS (P = 0.22) and OS (P = 0.15; data not shown). Combining independent biomarkers has previously shown to augment the predictive potential for DCB, as previously shown for plasma NGS with CD8+ cell levels [14]. When combining PD-L1 immunohistochemistry in pretreatment tumor biopsies with changes in ctDNA levels, these changes did not correlate with PD-L1 TPS, indicating that both markers are independent biomarkers (Fig. S10). In fact, combining changes in ctDNA with PD-L1 TPS ≥1% showed an eightfold longer PFS and more than twofold longer OS in patients with a decrease in ctDNA levels compared with patients who did not show a ≥30% decrease (Fig. 3). A subset of patients with a PD-L1 TPS of <1% with decreasing ctDNA levels seems to benefit from monotherapy as well (Table S4). Responders to immunotherapy in our study were observed both with high and low PD-L1

Fig. 3. Tumor response related to change in mutant ctDNA levels and PD-L1 TPS status. Kaplan-Meier plot displaying the (A, C) PFS and (B, D) OS of patients with a PD-L1 TPS of ≥1% (A, B) and < 1% (C, D) with decreasing (blue), or increasing or stable (red) ctDNA levels. The gray lines represent the entire PD-L1 cohort in the respective subgroups (not used in comparison of the different subgroups). Figure S9 shows the analysis of patients with decreasing, stable, increasing, and nondetectable ctDNA levels separately. Log-rank test, P-values of < 0.05 are considered significant. CtDNA decreasing, 30% less mutant copies at t1 compared with t0; no decrease in ctDNA, encompasses patients with ctDNA increase, ctDNA-negative and ctDNA stable.
tumors. The value of ctDNA decrease for monitoring treatment effect was independent of PD-L1 expression. Reck et al. [3] also reported an improved response upon decrease in ctDNA at t1 in a patient cohort with PD-L1 expression for first-line ICI treatment using a cutoff of TPS ≥ 50%. In line with this observation, evaluation of patients with PD-L1 TPS ≥ 50% and a decrease in ctDNA revealed even lower HRs (0.32 for PFS and 0.29 for OS; data not shown). However, in the current study 75% of patients was not treatment naïve. Patients who received previous lines of treatment generally show poorer response and survival times to ICI [4]. Despite the low number of patients in this study, this underscores the strong monitoring potential of change in ctDNA in combination with or without PD-L1 expression and warrants further prospective evaluation. The sensitivity of this combination monitoring tool might further be augmented by addition of other potentially predictive biomarkers such as the immunoscore, immune infiltration, cytokine signatures (e.g., interferon gamma, transforming growth factor beta), and somatic copy number alterations [42–44].

In patients with known driver mutations, these mutations are not retrieved in approximately 30% of matched cell-free plasma in various malignancies [45]. In line with these observations, in 31% of the included patients with metastasized disease the mutation detected in the pretreatment tumor biopsy was not detected in the corresponding ccfDNA sample at t0. No ctDNA was detected in 23% of the patients at both timepoints. Although the majority of patients without detectable ctDNA did not display a tumor response to treatment, their tumors seemed to have a more indolent course than those who did have specific ctDNA. This group of patients did have early PD in general, but OS was markedly better than for the ctDNA group showing stable levels or an increase at t1. The cause of absence of ctDNA in these plasma remains uncertain and proposed mechanisms include nonshedding tumors, increased clearance, shorter half-life, lack of sufficient analytical sensitivity, and stage of disease [37,45].

To monitor tumor response in ccfDNA using mutation-specific ddPCR analysis, sequencing of pretreatment tumor tissue is required to select a tumor-specific target. In 50% of advanced-stage NSCLC targetable (~20%) or nontargetable KRAS (~30%) driver mutations are detected with current commonly-used diagnostic NGS approaches [31,45]. However, mutations detected in the tumor may not always be present in plasma. Broadening routine clinical tissue NGS panels, for example, with the frequently mutated TP53 and STK11 genes, will increase the number of patients who can be effectively monitored for tumor response using plasma ccfDNA with single-gene approaches such as ddPCR. In this study, five patients with tumors containing multiple mutations at least one of these mutations could not be detected in the plasma. Selection of a mutation for monitoring purposes in plasma might lead to inconsistent results (Table S5). As such, several studies in lung cancer advocate the use of NGS analysis with a broad panel of markers on baseline plasma samples instead of a single selected marker. Targeting multiple mutations simultaneously also elevates the sensitivity of detecting ctDNA [12,46]. Indeed, the number of ctDNA-negative patients when using NGS approaches is substantially lower (4–8%) than was observed with our single variant assay [14,47]. Studies that used an NGS approach to monitor ctDNA in response to ICI therapy demonstrate a correlation between ctDNA dynamics and response similar to our findings [12,13,48].

Recently, three studies comprising larger cohorts of various malignancies including NSCLC treated with ICI reported on the association between serial ctDNA NGS testing and PFS, OS, clinical response, and clinical benefit [14–16]. However, in current clinical practice, NGS approaches on ccfDNA are not yet cost-effective for monitoring the course of treatment longitudinally. Single-target ddPCR analysis therefore provides a cost-effective alternative when the ctDNA target is detectable in the circulation. Longitudinal monitoring of a single tumor-derived variant beyond the currently proposed interval might assist in early detection of disease progression and its clinical applicability, probably in combination with multiple available biomarkers, should be investigated in future (prospective) studies. Besides, as ccfDNA is shed into circulation from various tissues, DNA fragments from hematopoietic and germline origin are prone to affect analytical results with NGS, as well as inconsistent preanalytical handling and sample processing [23,49–51]. Although the majority of clonal hematopoietic variants occur in nontargetable genes, these variants are also identified in targetable genes such as KRAS, BRAF, and PIK3CA as well [16]. Deep sequencing of plasma may therefore identify more mutations, but these might not all be derived from the tumor. To this extent, parallel sequencing of a patient-matched blood-borne reference material, for example, white blood cells, is of importance [50], further increasing the costs for routine clinical practice. Therefore, monitoring ctDNA with a ddPCR assay is as sensitive as NGS to monitor therapy response but in a cost-effective manner. However, ddPCR is only informative when tumor-derived DNA is present in circulation.
5. Conclusion

Altogether, decreasing mutant copies estimated with ddPCR were associated with longer PFS and OS compared with patients displaying increased or stable ctDNA levels. CtDNA dynamics in combination with PD-L1 status is a promising cost-effective approach to monitor DCB, PFS, and OS in patients treated with ICI. Measuring a single tumor-derived molecular aberration, when retrieved in the circulation, improves the early recognition of DCB and can assist in treatment decision making.

Acknowledgements

We thank all assisting technicians and students, in particular Maureen Toange, for their technical assistance. This work was supported by research grants of BMS (NTR 6158; BMS/CA209-759), Bio-Rad (Digital Biology Center, Pleasanton, CA, USA), and Biocartis (Mechelen, Belgium). The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Conflict of interest

NR is employed by the Dutch Cancer Society (KWF, Alpe D’HuZes research grant RUG 2013-6355). The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. LCK received research grants from AstraZeneca, nanoString, Invitae-ArcherDX, Bayer, and Roche, and an honorarium as a consultant or speaker for Pfizer, Novartis, AstraZeneca, BMS, nanoString, and Asuragen. ES has performed lectures for Bio-Rad, Novartis, Roche, Biocartis, Illumina, Pfizer, AstraZeneca, and Agena Bioscience, is consultant in advisory boards for AstraZeneca, Roche, Pfizer, Novartis, Bayer, Lilly, BMS, Amgen, Biocartis, Illumina, Agena Bioscience, and MSD/Merck, and received research grants from Pfizer, Biocartis, Invitae-ArcherDX, AstraZeneca, Agena Bioscience, BMS, Bio-Rad, Roche, Boehringer Ingelheim.

Author contributions

PL, BH, TJNH, and ES were involved in the conception and design of the study. PL, AM, MLAA, and NR performed the laboratory experiments. PL, BH, AE, WT, HJMG, LCK, TJNH, and ES were responsible for the patient data collection and data curation. PL, BH, LCK, TJNH, and ES prepared the original draft. All authors contributed to data interpretation, critically revised the article, and approved the final version.

Peer Review

The peer review history for this article is available at https://publons.com/publon/10.1002/1878-0261.13090.

Data accessibility

Supporting anonymized ddPCR and clinical response data are available for sharing upon reasonable request.

References

1 Passaro A, Attili I, Morganti S, Del Signore E, Giononcelli L, Spitaleri G, Stati V, Catania C, Curigliano G & de Marinis F (2020) Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: a critical review of published data. Cancer Treat Rev 89, 102085.
2 Schoenfeld AJ, Rizvi H, Bandlamudi C, Sauter JL, Travis WD, Rekhtman N, Plodkowski AJ, Perez-Johnston R, Sawan P, Beras A et al. (2020) Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol 31, 599–608.
3 Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe A et al. (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37, 537–546.
4 Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeño J, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S et al. (2019) Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 20, 1395–1408.
5 Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF et al. (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378, 2078–2092.
6 Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Domín J, Hui R, Hochmair MJ, Clingan P, Powell SF et al. (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38, 1505–1517.
7 Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Maizères J, Hermes B, Cicin I, Medgyessy
Monitoring ctDNA for treatment response prediction

B, Rodríguez-Cid J et al. (2020) A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 15, 1657–1669.

8 Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128.

9 Hopkins AM, Rowland A, Kichenadasse G, Wise MD, Gurney N, McKinnon RA, Karapetis CS & Sorich MJ (2017) Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer 117, 913–920.

10 Raja R, Kuozilla M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA & Randale K (2018) Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res 24, 6212–6222.

11 Boonstra PA, Wind TT, van Kruchten M, Schuuring E, Hopsers GAP, van der Wedken AJ, de Groot D-J, Schröder CP, Fehrmann RSN & Reyners AKL (2020) Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. Cancer Metastasis Rev 39, 999–1013.

12 Goldberg SB, Narayan A, Kole AJ, Decker RH, Teyis J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM et al. (2018) Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res 24, 1872–1880.

13 Guibert N, Jones G, Beeler JF, Plagnol V, Morris C, Mourlanette J, Delaunay M, Keller L, Rouquette I, Favre G et al. (2019) Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer 137, 1–6.

14 Nabete BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu L, Hui AB et al. (2020) Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363–376.e13.

15 Bratman SV, Yang SYNC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Abdul Razak A, Schegrova S et al. (2020) Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 1, 873–881.

16 Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS et al. (2020) Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov 10, 1842–1853.

17 Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Baum JM, Alley EW et al. (2019) Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol 5, 173–180.

18 Oxnard GR, Pawelzit CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM et al. (2014) Noninvasive detection of response and resistance in egfrmutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20, 1698–1705.

19 Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiarri R, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A et al. (2015) Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 10, 1437–1443.

20 Boonstra PA, Ter Elst A, Tibbesma M, Bosman LJ, Mathijsen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H et al. (2018) A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget 9, 13870–13883.

21 Lee JH, Long GV, Menzies AM, Lo S, Guminiski A, Whitbourne K, Peranece M, Scolyer R, Kefferd RF, Rizos H et al. (2018) Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 4, 717–721.

22 Lee JH, Menzies AM, Carino MS, McEvoy AC, Sandhu S, Weppler AM, Diefenbach RJ, Dawson S-J, Kefferd RF, Millward MJ et al. (2020) Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clin Cancer Res 26, 4064–4071.

23 Weber S, Spiegel B, Perakis SO, Ulaz CM, Abuja PM, Kashofer K, van der Leest P, Aguirre Azpuru M, Tamminga M, Brudzewsky D et al. (2020) Technical evaluation of commercial mutation analysis platforms and reference materials for liquid biopsy profiling. Cancers (Basel) 12, 1588.

24 Iijima Y, Hirotsu Y, Amemiya K, Ooka Y, Mochizuki H, Oyama T, Nakagomi T, Uchida Y, Kobayashi Y, Tsutsui T et al. (2017) Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer. Eur J Cancer 86, 349–357.

25 Zulato E, Attìli I, Pavan A, Nardo G, Del Bianco P, Boscolo Bragadin A, Verza M, Pasqualini L, Pasello G, Fassan M et al. (2020) Early assessment of KRAS mutation in ctDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. Br J Cancer 123, 81–91.

26 Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher C et al. (2017) Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol 28, 1996–2001.
Monitoring ctDNA for treatment response prediction

27 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arluck S, Gwyther S, Mooney M et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 45, 228–247.

28 van der Leest P, Boonstra PA, ter Elst A, van Kempen LC, Tibbesma M, Koopmans J, Miedema A, Tamminga M, Groen HJM, Reyners AKL et al. (2020) Comparison of circulating cell-free DNA extraction methods for downstream analysis in cancer patients. *Cancers (Basel)* 12, 1222.

29 Lamy P-J, van der Leest P, Lozano N, Becht C, Duboeuf F, Groen HJM, Hilgers W, Pourel N, Rifaela N, Schuuring E et al. (2020) Mass spectrometry as a highly sensitive method for specific circulating tumor DNA analysis in NSCLC: a comparison study. *Cancers (Basel)* 12, 3002.

30 Federatie Medisch Specialisten (2020) Richtlijn niet-kleincellig longcarcinoom. Retrieved from https://richtlijndatabase.nl/richtlijn/niet_kleincellig_longcarcinoom/startpagina_-_niet-kleincellig_longcarcinoom.html. November 12, 2020.

31 Steeghs EMP, Kroeze LI, Tops BBJ, van Kempen LC, ter Elst A, Kastner-van Raaij AWM, Hendriks-van Kreegunakan SJB, Hermens MJW, Jansen EAM, Nederlof PM et al. (2020) Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. *BMC Cancer* 20, 291.

32 Tamminga M, de Wit S, Hiltermann TJN, Timens W, Schuuring E, Terstappen LWMM & Groen HJM (2019) Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. *J Immunother Cancer* 7, 123.

33 Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Ashok Sivakumar IK, Bruhm DC, Rosner S et al. (2019) Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. *Cancer Res* 79, 1214–1225.

34 Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L et al. (2020) Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. *Nat Cancer* 1, 176–183.

35 Vessies DCL, Greuter MJE, van Rooijen KL, Linders TC, Lanfermeijer M, Ramkisoensong KL, Meijer GA, Koopman M, Coupé VMH, Vink GR et al. (2020) Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS 480 and BEAMing. *Sci Rep* 10, 8122.

36 Vivancos A, Aranda E, Benavides M, Elez E, Auxiliadora Gómez-España M, Toledano M, Alvarez M, Rosario Chica Parrado M, García-Barberán V & Diaz-Rubio E (2019) Comparison of the clinical sensitivity of the idylla platform and the OncoBEAM RAS CRC assay for KRAS mutation detection in liquid biopsy samples. *Sci Rep* 9, 8976.

37 Heitzer E, Haque IS, Roberts CES & Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. *Nat Rev Genet* 20, 71–88.

38 Sacher AG, Alden RS & Oxnard GR (2016) Early intervention in lung cancers with rapid plasma genotyping for EGFR and KRAS mutations—reply. *JAMA Oncol* 2, 1096–1097.

39 Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L et al. (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). *J Clin Oncol* 35, 3924–3933.

40 Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC et al. (2017) A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. *JAMA Oncol* 3, 1051–1058.

41 Dong Z-Y, Zhong W-Z, Zhang X-C, Su J, Xie Z, Liu S-Y, Tu H-Y, Chen H-J, Sun Y-L, Zhou Q et al. (2017) Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. *Clin Cancer Res* 23, 3012–3024.

42 Mildner F, Sopper S, Amann A, Pircher A, Pall G, Köck S, Naismith E, Wolf D & Gamberith G (2020) Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). *Crit Rev Oncol Hematol* 153, 102948.

43 Galon J & Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. *Nat Rev Drug Discov* 18, 197–218.

44 Tray N, Weber JS & Adams S (2018) Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application. *Cancer Immunol Res* 6, 1122–1128.

45 Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V et al. (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). *Lancet* 387, 1415–1426.

46 Abbosh C, Birkbak NJ & Swanton C (2018) Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection. *Nat Rev Clin Oncol* 15, 577–586.

47 Jiang J, Adams H-P, Lange M, Siemann S, Feldkamp M, McNamara S, Froehtler S, Yuang SJ, Yao L, Balasubramaniam A et al. (2020) Plasma-based
Monitoring ctDNA for treatment response prediction

P. van der Leest et al.

longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer. *BMC Cancer* **20**, 885.

48 Demuth C, Winther-Larsen A, Madsen AT, Meldgaard P & Sorensen BS (2018) A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. *Oncotarget* **9**, 31066–31076.

49 Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, Groelz D, Babayan A, Tibbesma M, Schlumpberger M et al. (2019) Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows. *Clin Chem* **66**, 149–160.

50 van der Leest P & Schuuring E (2020) The potential of combined mutation sequencing of plasma circulating cell-free DNA and matched white blood cells for treatment response prediction. *Mol Oncol* **14**, 487–489.

51 Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, Abida W, Juluru K, De Bruijn I, Hou C et al. (2019) High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. *Nat Med* **25**, 1928–1937.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** Patterns of response combining mutant ctDNA levels and tumor volume using CT scanning.

**Fig. S2.** Determination of most appropriate timepoints to optimally detect changes in ctDNA levels related to treatment response.

**Fig. S3.** Evaluation of case B-003.

**Fig. S4.** Correlation of the mutant copies per mL of plasma as determined with ddPCR and Idylla™ ctKRAS Mutation Assay.

**Fig. S5.** Mutant ctDNA levels at baseline.

**Fig. S6.** PFS and OS at different cut-offs to determine ctDNA decrease.

**Fig. S7.** PFS and OS is irrespective of *KRAS* mutations.

**Fig. S8.** Clinical response related to PD-L1 expression.

**Fig. S9.** Elaborate analysis of radiological response related to PD-L1 expression.

**Fig. S10.** No correlation between change in ctDNA levels and PD-L1 TPS.

**Table S1.** Overview of subgroup of 27 patients to determine the most appropriate timepoint after start ICI therapy to measure clinically relevant changes in ctDNA.

**Table S2.** Assays used for ddPCR analysis.

**Table S3.** CtDNA dynamics and clinical response.

**Table S4.** CtDNA dynamics and PD-L1 TPS score.

**Table S5.** Patients with multiple targetable mutations.